GSK

Blockchain in Pharma Unleashes a New Era of Trust and Efficiency – ET HealthWorld

by
Blockchain in Pharma Unleashes a New Era of Trust and Efficiency – ET HealthWorld

In the ever-evolving landscape of pharmaceuticals, where precision, safety, and trust are non-negotiable, blockchain technology emerges as the beacon of a revolutionary transformation. Beyond its cryptocurrency origins, blockchain is poised to redefine lifescience businesses, reshaping processes from the laboratory to the global supply chain. As per a Gartner report, blockchain’s business value in the pharmaceutical … Read more

Kotak initiates coverage on Mankind Pharma, sees 11% upside. 3 reasons why

by
Kotak initiates coverage on Mankind Pharma, sees 11% upside. 3 reasons why

Kotak Institutional Equities initiated coverage on Mankind Pharma stock with ‘Add’ rating for a price target of Rs 1,875. The domestic brokerage sees an 11% upside in the counter from current levels. “Mankind Pharma is well-positioned to further leverage its robust marketing prowess and reach. Within branded Rx, we expect a ramp-up of specialty and … Read more

Elon Musk’s Neuralink valued at about $5 billion despite long road to market – ET HealthWorld

by
Elon Musk’s Neuralink valued at about billion despite long road to market – ET HealthWorld

New Delhi: Elon Musk‘s brain implant startup Neuralink, which was valued at close to $2 billion in a private fundraising round two years ago, is now worth around $5 billion based on privately executed stock trades described to Reuters by five sources with knowledge of the matter. Some purchases by bullish investors boosted the valuation … Read more

Elon Musk’s Neuralink valued at about $5 billion despite long road to market – ET HealthWorld

by
Elon Musk’s Neuralink valued at about billion despite long road to market – ET HealthWorld

New Delhi: Elon Musk‘s brain implant startup Neuralink, which was valued at close to $2 billion in a private fundraising round two years ago, is now worth around $5 billion based on privately executed stock trades described to Reuters by five sources with knowledge of the matter. Some purchases by bullish investors boosted the valuation … Read more

Unilever’s soap opera: M&A, job cuts, Nelson Peltz joining board

by
Unilever’s soap opera: M&A, job cuts, Nelson Peltz joining board

Unilever appointed Nelson Peltz to its board on Tuesday as it engaged in talks about strategy with the American activist investor, who now holds a roughly 1.5% stake in the consumer goods giant. The maker of Dove soap and Magnum ice cream has had a bumpy few years, with shares falling about a quarter from … Read more

Britain’s GSK to buy Affinivax for up to $3.3 bln in vaccines push

by
Britain’s GSK to buy Affinivax for up to .3 bln in vaccines push

GSK said on Tuesday it would pay up to $3.3 billion to acquire privately held biopharmaceutical firm Affinivax to bolster its vaccine pipeline, a key area of focus as the British drugmaker prepares to separate its consumer unit. GSK, the world’s largest vaccine maker by sales, has been under pressure to shore up its pipeline. … Read more

Unilever eyes GSK’s consumer goods arm in possible 50 billion-pound deal

by
Unilever eyes GSK’s consumer goods arm in possible 50 billion-pound deal

Consumer goods giant said it had approached about buying the pharmaceutical group’s consumer goods arm, after a newspaper reported that a 50 billion-pound ($68.4 billion) bid it made had been rebuffed. Unilever, which has been under fire from some investors for the group’s underperforming share price, confirmed the approach about a potential acquisition of the … Read more

Omicron more transmissible than Delta: UK PM Boris Johnson to ministers

by
Omicron more transmissible than Delta: UK PM Boris Johnson to ministers

Early signs indicate that the Omicron variant of COVID-19 is more transmissible than the variant currently dominant in the UK, British Prime Minister Boris Johnson told his Cabinet ministers on Tuesday. Johnson’s official Number 10 Downing Street spokesperson told reporters in an account of the Cabinet meeting that Johnson reiterated it was still too early … Read more

GSK focused on split as cost checks, COVID-19 easings aid earnings

by
GSK focused on split as cost checks, COVID-19 easings aid earnings

Plans for GSK to split in two are “well underway” it said on Wednesday, as a cost clampdown and rising clinic visits for critical treatments after an easing of COVID-19 curbs helped it land better-than-forecast first-quarter earnings. GSK, which trails competitors in the coronavirus vaccines race, is under the microscope after a report that U.S. … Read more